Clinical Trial Identifier
NCT03987919
Tirzepatide, part of the SURPASS program.
Trial details
- Identifier
- NCT03987919
- Sponsor
- Eli Lilly
- Asset
- Tirzepatide
- Program
- SURPASS
- Phase
- Phase III
- Therapeutic area
- Type 2 Diabetes
Program context
SURPASS
HbA1c reductions of approximately 1.9 to 2.6 percentage points across the five trials at the highest dose; body-weight reductions of 7 to 13 kg; superiority over semaglutide 1 mg on both glycemic and weight endpoints in SURPASS-2.
Read the SURPASS spotlightTrial-level analysis lives in the program spotlight linked above. For the canonical registry record, including study design, eligibility, locations, and posted results, visit ClinicalTrials.gov.